All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The Psoriasis and Psoriatic Arthritis Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Psoriasis and Psoriatic Arthritis Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Psoriasis and Psoriatic Arthritis Hub cannot guarantee the accuracy of translated content. The Psoriasis and Psoriatic Arthritis Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Improvement in PROs after 3-year treatment with ustekinumab or TNFi: Results from the real-world PsABio study

Aug 29, 2023
Learning objective: After reading this article, learners will be able to compare the real-world effects of ustekinumab or a tumour necrosis factor inhibitor on patient-reported outcomes.

Psoriatic arthritis (PsA) affects ~30% of patients with psoriasis.1 PsA can cause pain, fatigue, and swollen and tender joints, which can impact quality of life.1 To provide a comprehensive understanding of treatment effectiveness, it is important to use patient reported outcomes (PROs) as a measurement of physical, psychological, and social functioning, alongside physician assessments in long-term clinical trials of PsA. Here, we summarize key findings from the multinational, prospective, real-world PsABio study (NCT02627768) which evaluated PROs after 3 years of treatment with ustekinumab or a tumor necrosis factor inhibitor (TNFi).

Study design

The final analysis of PsABio included 895 adult patients, with 439 randomized to ustekinumab and 456 randomized to TNFi. Of these, 219 receiving ustekinumab and 218 receiving TNFi remained on their original treatments for 3 years; the remainder switched or stopped treatment before this time. The following PROs were evaluated in patients who remained on treatment for 3 years:

  • EuroQol-5 dimensions questionnaire (EQ‑5D)‑3L health state: EQ-5D and EQ visual analog scale (EQ VAS)
  • 12-item PsA Impact of Disease questionnaire (PsAID-12)
  • Work Productivity and Activity Impairment for PsA questionnaire (WPAI)
  • Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA)


Baseline patient characteristics for patients who remained on the same treatment for 3 years are shown in Table 1.

Table 1. Key baseline patient characteristics*

Characteristic, % (unless otherwise stated)

(n = 219)

(n = 218)

Mean age, years



Mean BMI, mg/m2












Mean time since initial diagnosis, years



Line of bDMARD












Mean cDAPSA score, n



bDMARD, biologic disease-modifying anti-rheumatic drug; BMI, body mass index; cDAPSA, Clinical Disease Activity Index for Psoriatic Arthritis; TNFi, tumor necrosis factor inhibitor.

*Adapted from Gossec, et al.1

Patient-reported outcomes

Mean change from baseline to year 3 in EQ-5D score and overall PsAID-12 score are shown in Figure 1. EQ-5D and PSAID-12 scores improved across the 3 years for both treatments.

Figure 1. Mean score change from baseline to Year 3 in A PsAID-12 and B EQ-5D* 

EQ-5D, EuroQol-5 dimensions questionnaire; PsAID-12, 12-item PsA Impact of Disease questionnaire; TNFi, tumor necrosis factor inhibitor.
*Adapted from Gossec, et al.1

The percentage of patients employed at baseline and year 3 was similar in both treatment groups (54.5% and 55.9% for the ustekinumab group and 61.5% and 64.1% in the TNFi group, respectively). Patients treated with a TNFi had greater changes in WPAI outcomes compared with patients treated with ustekinumab; however, they also started from a lower baseline for each outcome. Mean changes in WPAI outcomes from baseline to year 3 are shown in Figure 2.

Figure 2. Mean score change from baseline to Year 3 in WPAI outcomes* 

TNFi, tumor necrosis factor inhibitor.
*Adapted from Gossec, et al.1

Link between PROs and efficacy endpoints

At 6 months and 3 years, patients who achieved cDAPSA low disease activity/remission had higher (better) EQ-5D scores compared with patients who did not achieve this endpoint. Similarly, patients who achieved cDAPSA low disease activity/remission had lower (better) PsAID-12 scores at Month 6 and Year 3 compared with those that did not achieve this endpoint. Work impairment scores, as measured by WPAI outcomes, were lower (better) at 6 months in patients achieving cDAPSA low disease activity/remission, minimal disease activity, and very low disease activity vs those not achieving these endpoints; similar scores were observed at 3 years.


Over 3 years of the PsABio real-world study, patients treated with both ustekinumab and TNFis demonstrated an improvement in PROs. Over the 3 years, work productivity increased steadily, with EQ-5D and PsAID-12 scores also improving for both groups. TNFi treated patients achieved larger improvements in PROs versus those treated with ustekinumab; however, this could have been influenced by differences in baseline measurements and factors influencing treatment decisions.

Work activity impairment, EQ-5D, and PsAID-12 scores were better in patients who achieved cDAPSA low disease activity/remission versus those who did not. Better scores were also seen in EQ-5D and PsAID-12 with cDAPSA remission, suggesting that an efficacious treatment may result in improved patient quality of life. However, further clinical trials evaluating this link are needed before conclusions can be made.

  1. Gossec L, Siebert S, Bergmans P, et al. Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study. Arthritis Res Ther. Online ahead of print. DOI: 1186/s13075-023-03058-y


Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox